JPY 4,953.00
+3.51%Price chart
Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18
Key dataSep 18, 2026
OpenJPY 4,990.00
From 52W high−6.93%
Volume2.10M
Market capJPY 1.40T
P/E (TTM)33.0x
P/S (TTM)1.6x
Div yield3.23%
Key dataSep 18, 2026
Open
JPY 4,990.00
From 52W high
−6.93%
Volume
2.10M
Market cap
JPY 1.40T
ValuationView details →
P/E (Fwd)
23.9x
EV/EBITDA
14.3x
P/E (TTM)
33.0x
RSI (14)
61.4
MomentumView details →
1D Return
+3.51%
YTD Return
+5.79%
Similar companies
Latest newsMore news →
Eisai and Biogen received Japanese manufacturing and marketing approval for a subcutaneous injection formulation of their Alzheimer's drug lecanemab (brand name Leqembi), which can be administered at home once weekly with a dedicated pen injector.4d agoExaWizards announced that its AI interactive role-playing service ExaBase Roleplay has been adopted by Eisai.5d agoEisai announced that China approved LEQEMBI (lecanemab) subcutaneous formulation as an initiation treatment for early Alzheimer's disease, enabling at-home administration.17d ago